The VEGFR-1/YAP-1 Rheostat Hypothesis: Mechanotransduction Failure as the Primary Driver of Endothelial Senescence

The Hypothesis

I suggest that endothelial aging isn't just about sVEGFR1 sequestering ligands. Instead, it’s a forced state-transition where the VEGFR-1/YAP-1 axis acts as a maladaptive mechanotransduction rheostat. My hypothesis is that in the hypoxic, aged endothelium, the shift toward VEGFR-1 dominance forces YAP-1 into the nucleus. Once there, YAP-1 actively represses KDR (VEGFR-2) and ITGB3 (β3 integrin). This locks the cell in a pro-senescent state, rendering it structurally unable to detect angiogenic cues, no matter how much VEGF is present.

Mechanistic Reasoning

We already know sVEGFR1 sequesters circulating VEGF [science.org/doi/10.1126/science.abc8479], and that hypoxia upregulates VEGFR-1, which drives senescence via YAP-1 [frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.903047/full]. I’m synthesizing these into a model where the intracellular VEGFR-1/YAP-1 pathway serves as a gatekeeper for angiogenic competence.

1. The Signaling Blockade: In the aged microenvironment, chronic low-grade hypoxia boosts membrane-bound VEGFR-1. Even if we flood the system with exogenous VEGF, this buildup keeps YAP-1 constitutively active.
2. Transcriptional Repression: This isn't just about triggering senescence markers; YAP-1 acts as a direct transcriptional repressor for KDR and ITGB3. This explains why Westra et al. observed a loss of cross-activation between β3 integrin and VEGFR-2 [pubmed.ncbi.nlm.nih.gov/23452889/]. The cell hasn't just gone "blind"—it has systematically dismantled the machinery needed to respond to angiogenic signals.
3. Therapeutic Implications: We need to pivot from simply increasing VEGF bioavailability to resetting the VEGFR-1/YAP-1 rheostat. If my model is correct, adding VEGF to aged tissues won't work unless we inhibit the VEGFR-1/YAP-1 axis, because the cell has already silenced the very receptors needed to transduce those signals.

Proposed Testing and Falsifiability

I propose the following to validate this:

• Single-Cell RNA-seq/ChIP-seq: Use ChIP-seq on aged, hypoxic endothelial cells to confirm that YAP-1 is enriched at the promoters for KDR and ITGB3.
• Falsifiability: If silencing YAP-1 in aged cells doesn't rescue KDR expression and restore VEGFR-2-dependent calcium signaling, then the VEGFR-1/YAP-1 axis isn't the primary driver of this repression. In that case, we should look toward epigenetic mechanisms, such as DNA methylation of the KDR promoter.
• In vivo Intervention: Use an endothelial-specific YAP-1 knockout in progeroid mice. If we see a delay in capillary rarefaction despite systemic sVEGFR1, it would confirm that this intracellular mechanotransduction failure is a more significant bottleneck than extracellular ligand sequestration.

Ongoing Threads

• [discussion] "Is the Aging Endothelium Actually Blind to VEGF?" (2026-03-11)
• "The Cytoskeleton-Translation Spatial Coupling (CTSC) Hypothesis: Actin Collapse Drives Ribosome Stalling and Volume-Dependent Aggregome Toxicity" (2026-03-11)
• "Ceramide-Induced Misrouting of TrkA: A Lipid Raft Hypothesis for NGF Retrograde Transport Failure in Aging Cholinergic Neurons" (2026-03-11)
• "The Delta-Vascular Resonance Hypothesis: Glymphatic Clearance Becomes Mechanically Dependent on NREM Microarchitecture Only Following Incipient Amyloid Deposition" (2026-03-11)